• About us
• Contact

Advertisement

Organisation › Details

Boehringer Ingelheim (Group)

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates in 47 countries and almost 37,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2005, Boehringer Ingelheim posted net sales of 9.5 billion euro while spending almost one fifth of net sales in its largest business segment Prescription Medicines on research and development. *

 

	Start	1885-01-01 established
	Industry	pharmaceutical
	Person	Barner, Andreas (Boehringer)
	Street	173 Binger Str.
	City	55216 Ingelheim
	Tel	+49-6132-770
		Address record changed: 2020-12-02
Basic data	Employees	I: 50,001 to 100,0 (2021-12-31)
	Currency	EUR
	Annual sales	20,618,000,000 (sales, net, consolidated (2021) 2021-12-31)
	Profit	3,406,000,000 (2021-12-31)
	Cash	2,296,000,000 (2011-12-31)
		* Document for »About Section«:
		Record changed: 2024-03-11

Advertisement

More documents for Boehringer Ingelheim (Group)

• [1] Boehringer Ingelheim. (1/3/24). "Press Release: Boehringer Ingelheim Partners with Ribo to Develop New Treatments for People with Liver Diseases". Ingelheim, Mölndal & Kunshan....
• [2] Centauri Therapeutics Ltd.. (2/16/22). "Press Release: Centauri Therapeutics Closes £24 million GBP Series A Investment Round". London....
• [3] Asgard Therapeutics AB. (11/9/21). "Press Release: Asgard Therapeutics Raises EUR 6M in Seed Financing to Exploit Direct in vivo Reprogramming". Lund....
• [4] Nanoform Finland Oyj. (8/17/21). "Press Release: Nanoform and Boehringer Ingelheim Execute Master Services Agreement". Munich....
• [5] NBE Therapeutics AG. (8/3/20). "Press Release: NBE-Therapeutics Appoints Bertrand Damour as Chief Executive Officer". Basel....
• [6] Boehringer Ingelheim. (6/8/20). "Press Release: New Consortium EUbOPEN Will Provide Tools to Unlock Disease Biology. 66 Million Euros to Generate Open-access Chemical Tools". Frankfurt & Ingelheim....
• [7] Genedata AG. (2/26/20). "Press Release: Leading Biopharma Experts Drive R&D Innovation and Process Efficiency at the Genedata Partner Symposium". Basel....
• [8] HepaRegenix GmbH. (1/21/20). "Press Release: HepaRegenix GmbH Secures Series B Financing in Excess of €11 Mio. to Advance First Drug Candidate to the Clinic". Tübingen....
• [9] Boehringer Ingelheim. (9/3/19). "Press Release: Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/Glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes". Ingelheim & Copenhagen....
• [10] NBE Therapeutics AG. (6/28/18). "Press Release: NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.